Psoriatic arthritis is inflammatory arthritis affecting some people with psoriasis. It causes joint pain, stiffness and swelling ranging from mild to severe with potential for joint damage.
Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Upadacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Filgotinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Describe your symptoms and get a structured AI clinical assessment — possible causes, urgency level, and recommended next steps.
Start Free AI Analysis →Content on this page is informed by evidence-based clinical sources including: